DBV Technologies S.A. (DBV.PA)
- Previous Close
1.2400 - Open
1.2500 - Bid --
- Ask --
- Day's Range
1.2180 - 1.2780 - 52 Week Range
1.0950 - 3.9160 - Volume
77,807 - Avg. Volume
70,769 - Market Cap (intraday)
117.329M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7600 - Earnings Date Jul 29, 2024 - Aug 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.74
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
www.dbv-technologies.comRecent News: DBV.PA
Performance Overview: DBV.PA
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DBV.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DBV.PA
Valuation Measures
Market Cap
119.25M
Enterprise Value
32.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.66%
Return on Equity (ttm)
-54.69%
Revenue (ttm)
14.94M
Net Income Avi to Common (ttm)
-79.51M
Diluted EPS (ttm)
-0.7600
Balance Sheet and Cash Flow
Total Cash (mrq)
101.53M
Total Debt/Equity (mrq)
6.29%
Levered Free Cash Flow (ttm)
-66.36M